A 64-year-old male smoker presents with painless gross hematuria. Cystoscopy reveals a 2-cm exophytic tumor on the bladder wall with a velvety red patch suggestive of carcinoma in situ (CIS) in the background. TURBT with deep muscle sampling is performed. Gross pathology shows a pink-tan growth with a slender fibrovascular stalk (marked **A** in the diagram) arising from the urothelial surface. Histology demonstrates arborizing papillary structures lined by thickened urothelium with high-grade nuclear pleomorphism and increased mitoses. The lamina propria is invaded (pT1); detrusor muscle is uninvolved. Based on the histological findings of the structure marked **A** and the presence of background CIS, which of the following is the most appropriate next step in management?
A. Neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy
B. Single immediate post-TURBT intravesical mitomycin-C, followed by surveillance cystoscopy every 3 months
C. Radical cystectomy with pelvic lymphadenectomy and urinary diversion
D. Intravesical BCG induction followed by maintenance therapy, with lifelong surveillance cystoscopy
Explanation
Why Intravesical BCG induction + maintenance is right
The structure marked A — the papillary frond with slender fibrovascular stalk — shows high-grade urothelial carcinoma with lamina propria invasion (pT1), which is non-muscle-invasive bladder cancer (NMIBC). The presence of background carcinoma in situ (CIS) and high-grade histology places this patient in the HIGH-RISK NMIBC category. According to EAU/AUA guidelines, high-risk NMIBC (high-grade Ta, T1, or CIS) requires intravesical BCG induction followed by maintenance therapy to reduce recurrence and progression risk. This is the standard of care for this risk stratification. Lifelong surveillance cystoscopy is mandatory.
Why each distractor is wrong
Single immediate post-TURBT intravesical mitomycin-C: This is appropriate for LOW-RISK NMIBC (low-grade Ta without CIS). The presence of high-grade T1 disease with background CIS makes this patient high-risk and requires BCG, not mitomycin-C alone.
Radical cystectomy with pelvic lymphadenectomy: This is reserved for BCG-UNRESPONSIVE high-risk NMIBC or muscle-invasive disease (≥T2). This patient has not yet received BCG induction; cystectomy is premature and not the first-line approach for newly diagnosed high-risk NMIBC.
Neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy: This is the standard approach for MUSCLE-INVASIVE BLADDER CANCER (≥T2). This patient's tumor is pT1 (lamina propria invasion only, detrusor uninvolved), which is non-muscle-invasive and does not warrant immediate neoadjuvant chemotherapy and cystectomy.
High-YieldNEET PG
High-grade T1 bladder cancer with CIS = high-risk NMIBC → BCG induction + maintenance (not mitomycin-C, not immediate cystectomy).
EAU and AUA Bladder Cancer Guidelines; Catto et al. Eur Urol. 2021; Chang et al. J Urol. 2021
Practice similar questions
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.
